Skip to content
Public researchFinquillOS
deep research

Deep Read — LLY · 2026-10-28

$LLY
6 days ago
Question asked
$LLY — How durable is Lilly's lead in GLP-1 obesity drugs — supply, pricing pressure, the oral pipeline — and how much of it is already priced in?

Eli Lilly (LLY) — GLP-1 Obesity Franchise Durability & What’s Priced In

As of: 2026-10-27 (Tuesday); US equity session closed. Q3 2026 results due 2026-10-29 before the open.
Scope: Durability of Lilly’s lead in GLP-1 obesity — supply, pricing pressure, oral pipeline — and how much is already in the stock.


Executive summary

Conclusion: Lilly’s clinical and commercial lead in incretin obesity/T2D remains intact heading into late 2026 — tirzepatide (Mounjaro/Zepbound) is the company’s core engine and still gaining on volume — but economic durability is already eroding at the net-price line, supply scarcity is no longer a moat, and the oral channel is a two-horse race rather than a Lilly exclusive. At roughly high-20s forward earnings and a ~$1.1T+ market cap, the stock embeds continued volume compounding and successful scale-up of orals; it does not appear to embed a severe net-price or share shock. The asymmetric risk is less “does GLP-1 work?” and more “how fast does net revenue per patient fall as Medicare, cash-pay, orals, and competitors mature?”

DimensionDurability score (1–5)One-line read
Clinical lead (efficacy)4Dual GIP/GLP-1 still best-in-class commercial agent; next-gen optionality exists but is not filing-confirmed as near-term
Supply / capacity3Constraints easing; expansion multi-year; shortage no longer a structural advantage
Pricing / payer2Volume up, realized prices down; Medicare discounted access from mid-2026; compounding overhang
Oral pipeline3Orforglipron (Foundayo) launched 2026 but early sales run-rate modest vs injectables; Novo oral Wegovy already in market
What’s priced in—High expectations; multiple below own 5-year mean but still rich vs pharma; little room for guidance disappointment at Q3 print

Recommendation: Hold / neutral on new capital at current levels for a diversified book; trim on strength if overweight. Prefer waiting for the 2026-10-29 print and 2027 guide for a cleaner read on net price, oral run-rate, and capacity. Long-term franchise quality is high; entry timing and net-price path dominate returns from here.

What would change the view (disconfirming):

  • More bullish: Sustained acceleration in oral prescriptions with stable injectable nets; clear evidence share gains vs Novo after both orals are scaled; 2027 guide that outpaces street without relying on price; retatrutide or other next-gen Phase 3 that re-opens efficacy gap.
  • More bearish: Faster net-price decline than volume gains (negative price/mix dominating); oral Foundayo stalling while Novo oral takes the pill channel; IRA selection or deeper Medicare cuts; any safety/label setback in incretins.

1. Franchise fundamentals (primary filings)

Scale and concentration (high confidence — SEC):

  • Mounjaro revenue $22.97bn in FY2025 (US $13.65bn, ex-US $9.32bn). [1]
  • Zepbound revenue $13.54bn in FY2025 (US $13.48bn, ex-US $0.06bn). [1]
  • Combined tirzepatide ~$36.5bn, 56% of total Lilly revenue in FY2025. [1]
  • By the six months ended 2026-06-30, Mounjaro + Zepbound were 65% of total revenue — concentration rising, not falling. [2]
  • US Mounjaro +53% YoY in FY2025; US Zepbound +174% YoY — both described as volume-driven. [1]
  • Company explicitly: revenue growth “driven primarily by increased volume, partially offset by lower realized prices,” with Mounjaro and Zepbound the primary drivers of both. [1][2]

Implication: The lead is real and still expanding in volume terms, but the P&L already shows the classic next phase of a category kill — price/mix headwind against volume. Obesity remains heavily US-skewed for Zepbound; Mounjaro has a more balanced geographic mix.

Management outlook language: Cardiometabolic products expected to remain a “significant and growing portion” of the business. [1] Manufacturing expansion “over the next several years.” [1]


2. Supply — durable advantage or fading bottleneck?

Filings (high confidence): Lilly is in a multi-year capacity build; it also flags counterfeit, misbranded, adulterated, and mass-compounded incretins as a business and supply risk and says it will consider lawsuits. [1]

Market context (moderate confidence — 2025–2026 commentary): Secondary reporting through 2026 describes easing injectable shortages versus the acute crisis years, ongoing plant/line ramps, and large GLP-1-related capex, with demand still able to outrun capacity in spots into 2027. Novo is on a parallel path — better supply than the trough, not unlimited. Treat site-level % capacity claims from trade press as directional, not audited.

Durability read:

  • Near-term (through 2027): Supply is a shared industry constraint, not a unique Lilly moat. As Lilly’s own capacity comes online, the “can’t get the drug” tailwind that supported pricing power and share stickiness fades.
  • Medium-term: Scale manufacturing and device/fill-finish know-how remain barriers vs smaller entrants, but not vs Novo.
  • Compounding: When FDA shortage designations lift, legitimate compounding should shrink; filings show Lilly still sees mass-compounded product as a live threat to brand integrity and potentially to demand leakage. [1]

Base rate: Category leaders that solve shortage typically see volume growth continue while net price and “urgency premium” compress — consistent with Lilly’s own volume-up / realized-price-down disclosure. [1]


3. Pricing pressure & payer dynamics

What is established:

  1. Realized price decline is already in the reported numbers for Mounjaro/Zepbound (FY2025 and H1 2026). [1][2]
  2. Medicare discounted obesity access: FY2025 10-K cites preliminary drug pricing agreements under which Medicare beneficiaries would have access to discounted Lilly obesity medicines by July 1, 2026. [1] Terms (list vs net, copay, covered products) are not fully specified in the excerpted filing language; treat headline copay figures in secondary press as unverified unless tied to CMS/Lilly primaries.
  3. IRA risk remains live in risk factors: unfavorable pricing/coverage determinations, including under the Inflation Reduction Act, may adversely impact the business; government-set prices for selected single-source drugs can accelerate revenue erosion. [1] Tirzepatide’s selection timing is a separate watch item — filings frame IRA as risk, not as immunity.
  4. Commercial / employer coverage for obesity remains the swing factor for Zepbound volumes; cash-pay and vial programs (widely reported in the category) expand access but usually at lower net.
  5. Competitive reference pricing with Novo (injectable and now oral) increases rebate intensity over time — standard US specialty dynamic.

Durability read: Pricing is the weakest pillar of the “lead.” Volume can still compound for years while NPV of the franchise is shaved by net-price. Medicare entry from mid-2026 is a structural volume positive and a structural net-price negative. That trade can be EPS-accretive if volume elasticity is high enough — it is not automatically margin-accretive.


4. Oral pipeline — does the pill extend the moat?

Filings (high confidence):

  • Orforglipron: US Commissioner’s National Priority Voucher; submitted under expedited review; licensed with Chugai; $1.5bn pre-launch inventory at 2025-12-31 — clear signal management expected a near-term US launch. [1]
  • Retatrutide: Not cited in the FY2025 10-K or H1 2026 10-Q per filing search used in this review — treat as pipeline optionality, not as a 2026 commercial driver. [1][2]

Market / launch status (moderate confidence — Oct 2026 previews):

  • Orforglipron commercialized as Foundayo (oral once-daily GLP-1) after ~April 2026 US approval, per multiple earnings-preview writeups. [3][4]
  • Q2 2026 Foundayo sales ~$98M in those previews — meaningful as a launch, tiny vs ~$36.5bn tirzepatide FY2025, and cited as below some higher street launch estimates (estimate noise is high). [3][5]
  • Novo oral Wegovy: US approval ~December 2025, launch ~January 2026 — Novo is not late to the oral channel. [4][6]

Strategic implications:

  • Oral expands the addressable market (needle-averse, primary-care throughput, potentially different payer designs) more than it “replaces” injectables near-term.
  • It does not restore scarcity moat; it opens a second competitive surface where Novo already fields a branded oral.
  • Small-molecule oral (orforglipron) vs peptide oral (semaglutide) differ in manufacturing cost curve, food/dosing constraints, and eventual LOE/generic path — long-term cost and LOE economics may favor a true small molecule, which is a latent Lilly advantage if efficacy/tolerability hold share. That LOE clock, however, also means earlier generic risk than biologics/peptides in some scenarios — a double-edged durability point.
  • Early Foundayo run-rate suggests the market should not underwrite oral as a 2026–27 EPS savior yet; it is a 2027–30 volume story.

Next-gen (retatrutide, competitor CagriSema, MariTide, etc.): Efficacy arms races can reset leadership, but until Phase 3 + label + supply + access land, they are call options, not cash flows. Do not underwrite retatrutide as filing-backed near-term revenue from the FY2025/H1’26 disclosures reviewed. [1][2]


5. Competitive landscape & share

Structure: Global branded obesity/T2D incretins remain a duopoly plus pipeline. Lilly’s dual agonist profile underpinned the clinical narrative that took share from semaglutide in head-to-head and real-world settings in prior years; that efficacy brand equity still matters for specialist preference.

As of late 2026 narrative:

  • Injectables: tirzepatide vs semaglutide still the commercial main event; both better supplied than in the shortage peak.
  • Orals: both Lilly and Novo are commercial — first-mover oral advantage is split/contested, not Lilly-only. [4][6]
  • Challengers (Amgen, Roche, Pfizer, Viking, Structure, others) are relevant to 2028+ share and pricing psychology even before launch, because payers use pipeline leverage in negotiations.

Patent / LOE: Not fully mapped in this pass from primary patent tables; standard watch is composition/device/formulation thickets for tirzepatide into the 2030s with litigation risk. Oral small-molecule LOE path may be shorter or differently contested than injectable peptide — material to terminal value.


6. Valuation context — how much durability is priced in?

Market snapshot (news-based, late October 2026; exact last close can differ by session):

  • Share price cited in a wide band around ~$1,270–$1,310 in Oct 23–24 articles; market cap cited ~$1.14T–$1.16T. [5][7]
  • Forward P/E cited ~28.6× vs a pharma industry group ~19×, and below a stated ~34.6× 5-year mean for LLY — i.e., premium to sector, de-rated vs own bubble-era multiple. [3]
  • Company FY2026 guidance (post-Q2 raise): revenue $85–87bn, adj. EPS $35.5–$36.5. [8]
  • Street Q3 2026 revenue center of gravity ~$22.1–22.6bn; EPS figures differ by outlet (reported vs normalized) — use company print, not preview EPS, as ground truth. [3][9]
  • Analyst PT average near ~$1,317 with extreme dispersion (~$891–$1,600) — high uncertainty, not consensus complacency. [7]
  • One desk framework: ~28× forward EPS on a rising 2026–28 EPS path. [5]

Rough embedded math (illustrative, not a forecast):
At ~28× and mid-guidance EPS mid-$30s, the market is paying for multi-year mid-20%+ earnings growth to fade toward high-teens without a hard landing — consistent with GLP-1 volume compounding and some price erosion, not with a price war or oral flop.

Reference class: Mega-cap platform biopharma with one franchise >50% of sales historically de-rate when (a) net price turns sustainably negative faster than volume, (b) a peer matches the next modality (here, oral), or (c) concentration risk collides with a policy shock. Lilly screens exposed to all three, partially already recognized via multiple compression from the 5-year mean. [3]


7. What is not priced in (or mispriced)

Evidence-tied gaps between narrative and numbers:

ItemMarket appears to assumeEvidence gap / mispricing risk
Oral upsideOrals meaningfully extend growth runway and multipleFoundayo ~$98M in Q2 2026 vs injectable tens of billions; Novo oral already live. Oral is real but not yet a second Zepbound. [3][4]
Net price pathVolume wins dominate EPSFilings already show lower realized prices; Medicare discounts from Jul 1, 2026. Street may still under-model 2027 net price if access mix skews government/cash. [1][2]
Supply as moatCapacity leadership sustains shareShortages easing industry-wide; capacity is table stakes. Advantage shifts to commercial + clinical + cost, not allocation.
ConcentrationDiversification later via pipelineTirzepatide 65% of H1’26 revenue — equity is a levered claim on one mechanism class. [2]
PolicyIRA manageable / distantRisk factors are blunt; selection or deeper Medicare bargains are left-tail not fully visible in a 28× multiple that still assumes smooth compounding. [1]
Next-gen efficacyOptional upside (retatrutide etc.)Not supported as near-term in FY25/H1’26 filings reviewed; if Phase 3 lands large, that may be upside not fully modeled; if competitors land first, downside not fully modeled. [1][2]
Multiple“Cheaper than peak” = safeBelow own 5-yr mean but still rich vs pharma; de-rating can continue if growth merely decelerates to “great.” [3]

Most important under-discussed risk: the market debates who wins GLP-1; the cash-flow question is what is net revenue per treated patient in 2028 with orals + Medicare + two scaled incumbents. Filings already point to price pressure; the stock still clears a growth-compounder multiple. [1][3]

Most important under-discussed support: manufacturing scale, brand in obesity care, dual-agonist efficacy equity, and small-molecule oral cost structure if Foundayo scales — plus a still-enormous untreated obesity population. Volume runway can remain multi-year even in a tougher price regime.


8. Catalysts (dated)

Date / windowEventWhy it matters
2026-10-29Q3 2026 earningsNet price commentary, Mounjaro/Zepbound split, Foundayo run-rate, any FY2026 guide tweak, 2027 color [3][8][9]
2H 2026–2027Capacity rampsConfirms volume ceiling vs surplus (pricing power)
Ongoing from Jul 2026Medicare discounted obesity accessVolume vs net realization trade [1]
2027Oral cohort maturityWhether Foundayo is category expander or share shredder vs injectable and vs Novo oral
Policy calendarIRA negotiation lists / CMS obesity policyLeft-tail on price
Pipeline printsCompetitor Phase 3 (CagriSema, MariTide, etc.) / any Lilly next-genLeadership psychology and long-term peak-sales cuts

9. Recommendation & rationale

Stance: Hold / neutral; do not chase; use Q3 and net-price disclosure to re-size.

Rationale (data-tied):

  1. Lead quality is high on volume and brand: FY2025 tirzepatide ~$36.5bn, H1’26 65% of sales, still volume-led. [1][2]
  2. Lead monetization is already under pressure: lower realized prices in filings; Medicare discounts; oral competition with Novo live in 2026. [1][4]
  3. Valuation (~28× fwd, ~$1.1T+ cap) prices durable compounding, not a stress case. [3][5][7]
  4. Oral is necessary for long-term durability but not yet sufficient at ~$98M quarterly scale to justify re-rating on its own. [3]
  5. Highest-utility near-term signal is management’s Q3 language on net price, inventory/capacity, and Foundayo trajectory (2026-10-29).

Positioning sketch (not personalized advice):

  • Core holders: Hold; hedge policy/net-price via size, not via abandoning the franchise thesis.
  • New money: Prefer post-print entry or pullbacks toward scenarios where FY2027 growth is priced closer to high-teens with explicit net-price fade — better margin of safety.
  • Overweight growth books: Trim into strength ahead of any guide that shows price/mix worse than volume upside.

Scenario range (qualitative):

  • Bull: Volume elasticity + oral expansion offset nets; 2027–28 EPS tracks high-growth desk paths; multiple stable ~25–30× → further upside but path-dependent on print.
  • Base: Volume strong, nets grind down mid-single-digits annually, oral builds slowly, multiple compresses modestly toward low-20s as growth decelerates → muted total return from current levels over 12 months, better 3–5 year if execution holds.
  • Bear: Net price + competitive oral + policy stack produce growth scare; multiple exits growth club → material drawdown despite solid absolute sales.

Strongest disconfirming evidence to monitor: three sequential quarters where price/mix subtracts more growth points than volume adds on tirzepatide, concurrent with Foundayo missing prescription exit-rate expectations and Novo gaining oral share.


Source list

[1] Eli Lilly Form 10-K, fiscal year ended 2025-12-31 (filed 2026) — Mounjaro/Zepbound revenue, 56% concentration, volume vs realized price, manufacturing expansion, orforglipron voucher/submission/$1.5bn inventory, Medicare discounted access by 2026-07-01, IRA and compounding risk factors.
https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm

[2] Eli Lilly Form 10-Q, period ended 2026-06-30 — tirzepatide 65% of revenue; continued volume-led growth language.
https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm

[3] Earnings preview (published 2026-10-27) — forward P/E ~28.59×, industry ~19×, 5-year mean ~34.60×; Q3 estimates; Foundayo commentary.
https://www.zacks.com/stock/news/3015631/buy-sell-or-hold-lly-stock-key-factors-to-watch-ahead-of-q3-earnings
https://ca.finance.yahoo.com/news/buy-sell-hold-lly-stock-115300408.html

[4] Category preview / competitive oral framing (Oct 2026) — Novo oral Wegovy timing; Lilly oral launch narrative.
https://www.tradingview.com/news/zacks:201d6915a094b:0-buy-sell-or-hold-lly-stock-key-factors-to-watch-ahead-of-q3-earnings

[5] Desk preview (published 2026-10-23) — valuation multiple framework; oral estimate discussion.
https://www.thestreet.com/investing/stocks/lly-eli-lilly-goldman-sachs-raises-12-month-stock-price-target-ahead-of-earnings

[6] Novo oral obesity launch timing as cited in Oct 2026 competitive previews (approval ~Dec 2025, launch ~Jan 2026).

[7] Market-cap / price / PT dispersion cites (Oct 22–24, 2026 articles).
https://www.tradingkey.com/news/market-movers/262236470-market-movers-lly-20261023

[8] Post-Q2 guidance raise to FY2026 revenue $85–87bn and adj. EPS $35.5–$36.5 (cited in 2026-10-26 preview).
https://www.barchart.com/story/news/8458544/dear-eli-lilly-stock-fans-mark-october-29-on-your-calendar

[9] Q3 2026 consensus revenue ~$22.1–22.6bn range across Oct 25–27, 2026 previews; print date 2026-10-29.
https://247wallst.com/investing/2026/10/25/3-massive-catalysts-that-could-ignite-an-eli-lilly-stock-rally-on-oct-29
https://www.investing.com/news/analyst-ratings/bernstein-raises-eli-lilly-stock-price-target-on-revenue-outlook-93CH-4973217


This dossier is research analysis, not investment advice. Figures from filings are authoritative for historicals; market quotes and secondary launch figures should be refreshed against the 2026-10-29 release and primary IR materials.

Claims staked · 4

  • At the Q3 2026 earnings release on 2026-10-29, Lilly will again characterize Mounjaro/Zepbound growth as driven primarily by increased volume and partially offset by lower realized prices, extending the FY2025 and H1 2026 pattern.
  • Lilly Q3 2026 total revenue will be at least $22.1 billion when reported on 2026-10-29, consistent with an intact volume-compounding tirzepatide franchise and the low end of the cited street range.
  • Foundayo (orforglipron) will not become a 2026–27 EPS savior at injectable scale: full-year 2027 Foundayo revenue will remain below $5 billion, in line with a slow 2027–30 oral build versus tirzepatide’s tens of billions.
  • Tirzepatide (Mounjaro + Zepbound) will still account for at least 50% of Lilly’s total revenue in FY2026, reflecting sustained—not diminishing—franchise concentration after 56% in FY2025 and 65% in H1 2026.
1views
0forks